Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
6,235,531
-
Number of holders
-
86
-
Total 13F shares, excl. options
-
13,716,818
-
Shares change
-
+1,101,094
-
Total reported value, excl. options
-
$278,786,220
-
Value change
-
+$19,416,739
-
Put/Call ratio
-
84%
-
Number of buys
-
45
-
Number of sells
-
-44
-
Price
-
$20.33
Significant Holders of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) as of Q4 2021
120 filings reported holding BTAI - BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q4 2021.
BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) has 86 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 13,716,818 shares
.
Largest 10 shareholders include FMR LLC (4,197,048 shares), ALLIANCEBERNSTEIN L.P. (1,508,768 shares), Artemis Investment Management LLP (1,410,382 shares), STATE STREET CORP (1,345,096 shares), BlackRock Inc. (1,289,654 shares), VANGUARD GROUP INC (1,022,331 shares), MASSACHUSETTS FINANCIAL SERVICES CO /MA/ (414,484 shares), GEODE CAPITAL MANAGEMENT, LLC (301,297 shares), MORGAN STANLEY (234,710 shares), and UBS Group AG (199,933 shares).
This table shows the top 86 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.